Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
Hlavní autor: | Leng, H |
---|---|
Další autoři: | Simon, K |
Médium: | Diplomová práce |
Jazyk: | English |
Vydáno: |
2019
|
Témata: |
Podobné jednotky
-
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
Autor: Mabilleau, G, a další
Vydáno: (2009) -
Stimulation of osteoclast formation by inflammatory synovial fluid
Autor: Adamopoulos, I, a další
Vydáno: (2006) -
Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
Autor: Mabilleau, G, a další
Vydáno: (2008) -
Expression of Receptor Activator of Nuclear – Kappa β Ligand in Patients with Metastatic Bone Disease
Autor: Magetsari, Rahadyan, a další
Vydáno: (2022) -
Maintenance therapy in multiple myeloma
Autor: Jean-Luc Harousseau
Vydáno: (2009-08-01)